The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients
Experimental Dermatology · 2023
DOI: 10.1111/exd.14901 ↗At a glance
Journal article in Experimental Dermatology, 2023. Written by Lucia Di Nardo and 13 co-authors. Institution: Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. Major MEDLINE topics: Melanoma, Circulating Tumor DNA, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Cited 9 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Despite the introduction of targeted (BRAFi/MEKi) and immune checkpoint inhibitors (ICIs) has significantly reduced the recurrence rate and improved the overall survival (OS) of patients with Stage III and IV melanoma, only a percentage will benefit of durable disease control. The aim of this study was to examine whether the levels of circulating tumour DNA (ctDNA) in plasma of advanced melanoma patients undergoing BRAFi/MEKi or ICIs vary according to the patients' survival outcomes (i.e. progression‐free survival (PFS) and OS) and disease progression. Plasma samples of Stage III‐IV melanoma patients were collected at baseline (treatment initiation) and thereafter every 3 months. Circulating BRAF V600E/K and NRAS Q61R/K mutations were analysed through droplet digital PCR (ddPCR, Bio‐Rad) in a total of 177 plasma samples from 48 melanoma patients (19 Stage III, 29 Stage IV). Baseline ctDNA concentration was significantly associated with OS (HR = 1.003, 95% CI = 1.000–1.006, p = 0.043) and PFS (HR = 1.004, 95% CI = 1.000–1.007, p = 0.029) independent of clinical‐prognostic confounders. For each unit increase in the ∆ctDNA (concentration difference between the last follow‐up and baseline) there was a 24% increased risk of disease progression, irrespective of treatment type and stage at diagnosis (OR = 1.24, 95% CI = 1.03–1.49, p = 0.020, AUC = 0.93). Patients with reduction of ctDNA level from baseline to the last follow‐up had longer OS (HR = 0.14; 95% CI = 0.05–0.44, p = 0.001) and PFS (HR = 0.08; 95% CI = 0.03–0.27, p < 0.0001) compared to patients with increased ctDNA, including adjustment for confounding factors. Our findings suggest that variation of ctDNA over time during melanoma treatment reflects the clinical outcome and tumour response to therapy and might be helpful in clinical monitoring.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
- UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A, Gemelli - IRCCS, Rome, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Medical Oncology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Surgery & Cancer, Imperial College London, London, UK.
- Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
ORCID profiles: Alessio Cortellini
Cite
APA
Di Nardo, L., Del Regno, L., Di Stefani, A., Mannino, M., Fossati, B., Catapano, S., Quattrini, L., Pellegrini, C., Cortellini, A., Parisi, A., Capoluongo, E., Autilio, C., Fargnoli, M. C., & Peris, K. (2023). The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. https://doi.org/10.1111/exd.14901
Vancouver
Di Nardo L, Del Regno L, Di Stefani A, Mannino M, Fossati B, Catapano S, et al. The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. 2023. doi:10.1111/exd.14901
BibTeX
@article{DiNardo2023,
author = {Di Nardo, Lucia and Del Regno, Laura and Di Stefani, Alessandro and Mannino, Maria and Fossati, Barbara and Catapano, Silvia and Quattrini, Laura and Pellegrini, Cristina and Cortellini, Alessio and Parisi, Alessandro and Capoluongo, Ettore and Autilio, Chiara and Fargnoli, Maria Concetta and Peris, Ketty},
title = {The dynamics of circulating tumour DNA ( ctDNA ) during treatment reflects tumour response in advanced melanoma patients},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14901}
}
EUVIMED